2 studies found for:    18541894 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
Condition: Differentiated Thyroid Cancer
Intervention:
2 Recruiting Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Condition: Thyroid Carcinoma
Interventions: Drug: Continuous pazopanib (Arm A);   Drug: Intermittent pazopanib (Arm B)

Indicates status has not been verified in more than two years